The study identifies serological markers of active fibrosis in diastolic heart failure that correlate with disease severity, suggesting potential diagnostic and therapeutic targets.
These data demonstrate serological evidence of an active fibrotic process in DHF, which is more marked in more severe diastolic dysfunction. This observation may help explain the pathophysiology of DHF and may suggest new avenues for diagnostic and therapeutic intervention.
Martos et al. (Tue,) studied this question.